Avenge Bio (Series A)

Funding Details
Awarder
Inbox
Date Award
March 02, 2022
Vertical
Biotechnology
Funding URL
View Funding Page

Company Info
Founders
Michael Heffernan
Company Description
Avenge Bio is an oncology-focused biotechnology company developing transformative cell-based immunotherapeutic products for the treatment of intractable solid tumors by incorporating its LOCOcyte platform. The LOCOcyte platform leverages proprietary engineered cells delivered to the local tumor environment that generate high concentrations of immune effector molecules in proximity to the tumor.
Market
Oncology
Coinvestors
CAM Capital, Longitude Capital, Pappas Capital, Perceptive Advisors, Rock Springs Capital

Links
Back to Home Back to Biotechnology Deals View Funding Announcement